Drug–Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open‐Label Study
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6191 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Li Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Rifampin, HIV Fusion Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Frontier Biotechnologies Inc.
Abstract (Originalsprache)
Albuvirtide (ABT) is a novel long‐acting fusion inhibitor for human immunodeficiency virus type 1 (HIV‐1), and may be co‐administered with rifampicin (RIF) in patients concurrent with tubercle bacillus and HIV‐1. This study was conducted to investigate the pharmacokinetic effect of co‐administration of the two drugs. In the study, 24 healthy volunteers were randomized to receive ABT alone or with RIF. Plasma concentrations were measured using liquid chromatography‐tandem mass spectrometry for RIF and competitive enzyme‐linked immunosorbent assay for ABT. Co‐administration with RIF increased the maximum concentration (C max ) of ABT by 6.93%, and the area under the plasma concentration–time curve (AUC) from time 0 to the last quantifiable concentration (AUC 0‐t ) by 21.31%; the geometric mean ratio values (GMRs) for C max and AUC 0‐t of ABT when co‐administered with RIF, relative to administered alone, were 106.93% (90% confidence interval [CI] 97.53%‐117.23%) and 121.31% (90% CI 108.68%‐135.40%), respectively. Co‐administration with ABT decreased the steady‐state C max (C max,ss ) of RIF by 10.19%, and the steady‐state AUC from time 0 to 24 h (AUC 0‐24 h,ss ) by 19.93%; the GMRs for C max,ss and AUC 0‐24 h,ss of RIF when co‐administered with ABT, relative to administered alone, were 89.81% (90% CI, 79.97%‐104.79%) and 80.07% (90% CI 75.68%‐84.72%), respectively. The time to reach Cmax (Tmax) of both ABT and RIF demonstrated no statistically significant difference, whether administered alone or concurrently. The pharmacokinetics profiles of both RIF and ABT changed to some extent when co‐administered, while no clinically significant impact on these two drugs was observed, indicating that ABT and RIF can be used together without necessitating dose adjustments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Infectious Disease and Immunology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Clinical Research Department, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
ORCID-Profile: Li Zhang, Xian-Min Meng
Förderung
- Frontier Biotechnologies Inc
Zitieren
APA
Zhang, L., Chen, J., Lin, X. Y., Lu, Y., Wu, Y., Wu, Y. J., & Meng, X. M. (2025). Drug–Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open‐Label Study. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6191
Vancouver
Zhang L, Chen J, Lin XY, Lu Y, Wu Y, Wu YJ, et al. Drug–Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open‐Label Study. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6191
BibTeX
@article{Zhang2025,
author = {Zhang, Li and Chen, Jun and Lin, Xiao-Yan and Lu, Yan and Wu, Yan and Wu, Yi-Jun and Meng, Xian-Min},
title = {Drug–Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open‐Label Study},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6191}
}
EUVIMED